MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023

Research collaboration reveals promising drug candidate for treatment of blood cancers

by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead

Updated on: December 20,2023

Research collaboration reveals promising drug candidate for treatment of blood cancers

by Children's Cancer Institute AustraliaCredit: CC0 Public DomainToday, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a lead

Updated on:December 20,2023

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on: November 07,2023

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on:November 07,2023

New antibody shows strong potential as treatment against pancreatic cancer

New antibody shows strong potential as treatment against pancreatic cancerbyTranslational Genomics Research InstituteSIWA318H treatment depletes p16INK4apositive cells and reduces αSMA exp

Updated on: October 30,2023

New antibody shows strong potential as treatment against pancreatic cancer

New antibody shows strong potential as treatment against pancreatic cancerbyTranslational Genomics Research InstituteSIWA318H treatment depletes p16INK4apositive cells and reduces αSMA exp

Updated on:October 30,2023

PAD4 inhibition in neutrophils halts cancer progression and metastasis

byThe Wistar InstituteCancer Cell Dividing. Credit: The Wistar InstituteResearchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therap

Updated on: December 17,2023

PAD4 inhibition in neutrophils halts cancer progression and metastasis

byThe Wistar InstituteCancer Cell Dividing. Credit: The Wistar InstituteResearchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therap

Updated on:December 17,2023

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on: December 19,2023

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on:December 19,2023

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on: December 22,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on:December 22,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on: December 20,2023

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on:December 20,2023

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on: October 14,2023

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on:October 14,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on: December 21,2023

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

by Compuscript LtdGraphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11

Updated on:December 21,2023